← Leaderboards
Colin Koziol
Cedars-Sinai Medical Center
$114,896
Attributed
$114,896
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $38.9K · FY2020–22$50K$37.5K$25K$12.5K$0
'20
'21
'22
Funding mix
By agency
NIH$114,896 · 1
By mechanism
F31$114,896 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Crispr/Cas Technology”
- William H. Peranteau · Children'S Hosp Of Philadelphia$16,284,236
- Crystal Mackall · Children'S Hosp Of Philadelphia$13,090,386
- Jacqueline K White · Jackson Laboratory$11,881,166
- Jesse M Engreitz · Stanford University$8,776,071
- Peng Jiang · Rutgers, The State Univ Of N.J.$6,578,144
- Yin Shen · University Of California, San Francisco$6,515,212
Research focus
Crispr/Cas TechnologyAffectAllelesAnti-Inflammatory AgentsAutoantibodiesAlveolarAlveolar Type Ii CellAutoimmunityAutomobile DrivingAutophagocytosisBiological Adaptation To StressBronchiolitisCarrier ProteinsCell PhysiologyCellsCell TypeCellular StressCharacteristicsChronicCoatomer ProteinCodeComplexConsensusDefect
Grant awards (3)
Characterization of pulmonary progenitor cell dysfunction in COPA syndrome$38,948
F31 · FY2022 · HL · contact PI
Characterization of pulmonary progenitor cell dysfunction in COPA syndrome$38,232
F31 · FY2021 · HL · contact PI
Characterization of pulmonary progenitor cell dysfunction in COPA syndrome$37,716
F31 · FY2020 · HL · contact PI